(Corrects to 'Tuesday' from 'Monday' in first paragraph)
Dec 27 Seattle Genetics Inc said on
Tuesday that four people had died in trials testing its
experimental cancer drug, prompting the U.S. Food and Drug
Administration to impose a clinical hold on several early-stage
The drug, vadastuximab talirine, is being tested to treat
acute myeloid leukemia, a type of blood cancer.
Six patients have been identified with liver toxicity, and
four have died, the company said.
The clinical holds have been initiated to evaluate the
potential risk of liver toxicity in patients who were treated
with the drug and underwent stem cell transplant surgery either
before or after the treatment.
(Reporting by Divya Grover in Bengaluru; Editing by Shounak